



I/LA30-A

Immunoassay Interference by Endogenous Antibodies; Approved Guideline

This guideline discusses the nature and causes of interfering antibodies, as well as their effects on immunoassays and mechanisms by which interference occurs. Methods to identify and characterize the interferences are addressed along with assessment of methods used to eliminate interference.

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.

Clinical and Laboratory Standards Institute

Setting the standard for quality in clinical laboratory testing around the world.

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing clinical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement, but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advancements in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential, and may be submitted by anyone, at any time, on any document. All comments are addressed according to the consensus process by a committee of experts.

Appeals Process

If it is believed that an objection has not been adequately addressed, the process for appeals is documented in the CLSI Standards Development Policies and Process document.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For further information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute
950 West Valley Road, Suite 2500
Wayne, PA 19087 USA
P: 610.688.0100
F: 610.688.0700
www.clsi.org
standard@clsi.org

ISBN 1-56238-658-1
ISSN 0273-3099

I/LA30-A
Vol. 28 No. 6
Replaces I/LA30-P
Vol. 27 No. 9

Immunoassay Interference by Endogenous Antibodies; Approved Guideline

Volume 28 Number 6

Joan H. Howanitz, MD
Johan Bjerner, MD, PhD
Nina M. Chace, MS
Bernard C. Cook, PhD, DABCC, FACB
Pradip Datta, PhD, DABCC
Robert C. Doss, PhD
Steven C. Kazmierczak, PhD, DABCC, FACB
Stanley S. Levinson, PhD
Vadiraja V. Murthy, PhD
Robert M. Nakamura, MD
Wadid Sadek, PhD
Jennifer A. Snyder, PhD

Abstract

Clinical and Laboratory Standards Institute document I/LA30-A—*Immunoassay Interference by Endogenous Antibodies; Approved Guideline* presents information on the origin, nature, and prevalence of circulating endogenous antibodies, which cause interference with immunoassay results. The mechanisms of the interference along with some specific examples are included. To address the problem, recommendations for regulatory bodies, reagent manufacturers, and laboratorians are provided.

Clinical and Laboratory Standards Institute (CLSI). *Immunoassay Interference by Endogenous Antibodies; Approved Guideline*. CLSI document I/LA30-A (ISBN 1-56238-658-1). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2008.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at www.clsi.org. If your organization is not a member and would like to become one, and to request a copy of the catalog, contact us at: Telephone: 610.688.0100; Fax: 610.688.0700; E-Mail: customerservice@clsi.org; Website: www.clsi.org.



Copyright ©2008 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, companion product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to permissions@clsi.org.

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedure manual at a single site. To request permission to use this publication in any other manner, e-mail permissions@clsi.org.

Suggested Citation

CLSI. *Immunoassay Interference by Endogenous Antibodies; Approved Guideline*. CLSI document I/LA30-A. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.

Proposed Guideline

March 2007

Approved Guideline

February 2008

ISBN 1-56238-658-1
ISSN 0273-3099

Contents

Abstract.....	i
Committee Membership.....	iii
Foreword.....	vii
1 Scope.....	1
2 Introduction.....	1
3 Standard Precautions.....	1
4 Terminology.....	2
4.1 Definitions.....	2
4.2 Acronyms/Abbreviations.....	2
5 Origin and Nature of Interfering Antibodies.....	3
5.1 Prevalence.....	4
6 Mechanisms and Types of Interference.....	6
6.1 Detecting the Presence of Interfering Antibodies.....	7
6.2 Origins of Interfering Antibodies.....	9
6.3 Mechanism of the Formation of Interfering Antibodies.....	10
6.4 Incidence of Heterophile and Antianimal Antibodies.....	10
7 Effects of Interference.....	11
7.1 Types of Assays.....	11
7.2 Various Matrices.....	12
7.3 Assay Examples.....	12
8 Control Measures to Reduce Interferences.....	18
8.1 Assay Design Considerations.....	19
8.2 Testing.....	20
8.3 Responsibilities in Prevention, Identification, and Elimination of Interference.....	20
References.....	22
Summary of Delegate Comments and Subcommittee Responses.....	25
The Quality Management System Approach.....	29
Related CLSI Reference Material.....	29

Foreword

This guideline describes methods for identification and potential elimination of immunoassay interference caused by antibodies in patient specimens. These circulating endogenous antibodies can cause falsely increased or decreased results for analytes measured by immunoassay. Interferences are assay-dependent and often go unrecognized, thus leading to misinterpretation of results. When results falsely signify an underlying medical condition, unnecessary follow-up testing or treatment can occur. Assay interferences also can cause failure to recognize disease. Even though in the design and development of immunoassays, the issue of interfering antibodies has been addressed, complete elimination of interference has not been possible. Clinicians thus need to be aware of the limitations of immunoassays. Test results that are inconsistent with other sources of medical information and do not fit the clinical picture should be considered suspect. This requires awareness of this type of problem and good communication for both laboratory personnel and the patient's physician.

Key Words

Antianimal antibodies, autoantibodies, endogenous antibodies, heterophile antibodies, immunoassay, interference

SAMPLE

Immunoassay Interference by Endogenous Antibodies; Approved Guideline

1 Scope

This guideline discusses the nature and causes of interfering antibodies as well as their effects on immunoassays and mechanisms by which interference occurs. Methods to identify and characterize the interferences are addressed along with assessment of methods used to eliminate interference. This document suggests guidelines for regulatory bodies, manufacturers, and laboratorians in their roles identifying and eliminating endogenous interfering antibodies in patient specimens. Although examples of specific assay interferences are included, the document does not intend to describe all methods or analytes where antibody interference has been reported. The guideline does not address other types of immunoassay interferences, such as hemolysis, cross-reacting substances, and drug interference, except when the drug is an antibody. The intended users of the guideline are organizations responsible for regulatory oversight of immunoassay reagent production, manufacturers of immunoassay reagents, and laboratorians performing immunoassays.

2 Introduction

Because of their sensitivity and specificity, immunoassays are important diagnostic tools allowing measurement of a wide variety of analytes. Immunoassays, however, are subject to a number of interferences including those caused by circulating endogenous antibodies. Interference can occur because of heterophile antibodies, antianimal antibodies, or autoantibodies. The interfering antibodies can give rise to falsely high or, less commonly, falsely low results. The erroneous result is recognized as being inconsistent with the patient's clinical picture, but often it is clinically difficult or impossible to recognize an assay result as spurious. Additionally, it may be difficult to ascertain by commonly used laboratory procedures that a given result is erroneous. The laboratory procedures generally used to identify the presence of interfering antibodies are demonstration of a nonlinear response to dilutions, addition of nonimmunoglobulin protein to block the interfering antibody, or use of an alternate immunoassay. None of these commonly used procedures, however, can identify interference reliably in all cases. The magnitude of the problem of antibody interference is unknown with certainty, because wide variation in prevalence has been described depending on the detection methods used and the populations studied. Circulating endogenous antibodies may arise from incidental or occupational exposure to foreign protein, use of antibodies as diagnostic or therapeutic agents, following infection or vaccination, or for unknown reasons. The interference is variable, complex, and unpredictable because of the wide range of affinities and avidities found among the various endogenous antibodies that can be encountered. The antibodies may react with the analyte, the reagent antibodies, or both. There are also reports of antibodies interfering with the immunoassay detection systems. Interfering antibodies are not only difficult to recognize but are problematic to eliminate. Nonlinear response to dilutions cannot always be identified in the presence of interfering antibodies. The interfering antibodies can have high titer or avidity and thus, it may be difficult to eliminate the interference with blocking agents. Interfering antibodies may react with various types of assay antibodies and thus may interfere in different assay types. The intent of this document is to increase awareness of the problem of interfering antibodies and to suggest approaches to minimize their impact on patient care. The intent of the subcommittee is to repeat pertinent information under various subheadings in the document.

3 Standard Precautions

Because it is often impossible to know what isolates or specimens might be infectious, all patient and laboratory specimens are treated as infectious and handled according to "standard precautions." Standard precautions are guidelines that combine the major feature of "universal precautions and body substance isolation" practices. Standard precautions cover the transmission of all infectious agents and thus are

more comprehensive than universal precautions, which are intended to apply only to transmission of blood-borne pathogens. Standard and universal precaution guidelines are available from the US Centers for Disease Control and Prevention.¹ For specific precautions for preventing the laboratory transmission of all infectious agents from laboratory instruments and materials and for recommendations for the management of exposure to all infectious disease, refer to CLSI document M29.²

4 Terminology

4.1 Definitions

affinity – the force of attraction between molecules.

antianimal antibodies – antibodies that show strong avidity for test antibodies of one species, but the antibody may cross-react with immunoglobulins from other species.

antibody – a substance formed in the body in response to a foreign protein (an antigen) that interacts only with that substance; however, it may also bind to structurally related substances.

avidity – net affinity of all binding sites of antibodies.

cryoglobulin – a mixture of globulins that precipitates when cooled and dissolves when reheated to body temperature.

heterophile antibodies – antibodies produced against poorly defined antigens that react with immunoglobulins from two or more species.

rheumatoid factors – antibodies that bind to the constant or Fc portion of other immunoglobulins.

secondary antibody – an antibody that recognizes and binds a primary antibody.

4.2 Acronyms/Abbreviations

Ab	(Ag-specific) antibody
AFP	alpha-fetoprotein
Ag	antigen
ALG	antilymphocyte globulin
CB	competitive protein binding
CK-MB	creatine kinase MB isoenzyme
CLIA	chemiluminescent immunoassay
CRP	C-reactive proteins
EBV	Epstein-Barr virus
ELISA	Enzyme-Linked Immunosorbent Assay
FIA	fluoroimmunoassay
FPIA	fluorescence polarization immunoassay
FSH	follicle stimulating hormone
HAAA	human antianimal antibodies
HAMA	human antimouse antibodies
HARA	human antirabbit antibody
HBV	hepatitis B virus
hCG	human chorionic gonadotropin
IgG	immunoglobulin G
IgM	immunoglobulin M
LH	luteinizing hormone

The Quality Management System Approach

Clinical and Laboratory Standards Institute (CLSI) subscribes to a quality management system approach in the development of standards and guidelines, which facilitates project management; defines a document structure via a template; and provides a process to identify needed documents. The approach is based on the model presented in the most current edition of CLSI/NCCLS document HS1—*A Quality Management System Model for Health Care*. The quality management system approach applies a core set of “quality system essentials” (QSEs), basic to any organization, to all operations in any health care service’s path of workflow (ie, operational aspects that define how a particular product or service is provided). The QSEs provide the framework for delivery of any type of product or service, serving as a manager’s guide. The QSEs are:

Documents & Records Organization Personnel	Equipment Purchasing & Inventory Process Control	Information Management Occurrence Management Assessments—External & Internal	Process Improvement Customer Service Facilities & Safety
--	--	---	--

I/LA30-A addresses the QSEs indicated by an “X.” For a description of the other document listed in the grid, please refer to the Related CLSI Reference Material section below.

Documents & Records	Organization	Personnel	Equipment	Purchasing & Inventory	Process Control	Information Management	Occurrence Management	Assessments—External & Internal	Process Improvement	Customer Service	Facilities & Safety
					X M29						M29

Adapted from CLSI/NCCLS document HS1—*A Quality Management System Model for Health Care*.

Related CLSI Reference Material*

M29-A3 **Protection of Laboratory Workers From Occupationally Acquired Infections; Approved Guideline—Third Edition (2005).** Based on US regulations, this document provides guidance on the risk of transmission of infectious agents by aerosols, droplets, blood, and body substances in a laboratory setting; specific precautions for preventing the laboratory transmission of microbial infection from laboratory instruments and materials; and recommendations for the management of exposure to infectious agents.

* Proposed-level documents are being advanced through the Clinical and Laboratory Standards Institute consensus process; therefore, readers should refer to the most current editions.



Explore the Latest Offerings from CLSI!

As we continue to set the global standard for quality in laboratory testing, we're adding initiatives to bring even more value to our members and customers.



Power Forward with this Official Interactive Guide

Fundamentals for implementing a quality management system in the clinical laboratory.



Find Membership Opportunities

See the options that make it even easier for your organization to take full advantage of CLSI benefits and our unique membership value.



Visit the CLSI U Education Center

Where we provide the convenient and cost-effective education resources that laboratories need to put CLSI standards into practice, including webinars, workshops, and more.



Shop Our Online Products

Including eCLIPSE Ultimate Access™, CLSI's cloud-based, online portal that makes it easy to access our standards and guidelines—*anytime, anywhere.*

For more information, visit www.clsi.org today.

SAMPLE



CLINICAL AND
LABORATORY
STANDARDS
INSTITUTE®

950 West Valley Road, Suite 2500, Wayne, PA 19087 USA

P: 610.688.0100 Toll Free (US): 877.447.1888 F: 610.688.0700

E: customerservice@clsi.org www.clsi.org

ISBN 1-56238-658-1